SCHEDULE: CASI Pharma Director Offers $1.15/Share to Go Private

Dr. Wei-Wu He, a director of CASI Pharmaceuticals, Inc., has submitted an updated non-binding proposal to acquire all publicly held ordinary shares for $1.15 per share in cash, aiming to take the company private.

Summary

• Dr. Wei-Wu He, a director of CASI Pharmaceuticals, Inc., proposed to acquire all outstanding ordinary shares not already owned by him or his affiliates.
• The updated non-binding proposal, dated January 9, 2026, offers US$1.15 per share in cash.
• This price represents a 30% premium to the average closing price over the last 30 trading days.
• The acquisition would involve approximately 17,810,338 publicly held shares (16,810,338 ordinary shares + 1,000,000 shares underlying pre-funded warrants).
• The total transaction value is estimated at approximately US$20.5 million.
• If completed, CASI Pharmaceuticals' ordinary shares would be delisted from Nasdaq and registration terminated.
• Funding is expected to be a combination of debt and equity, with existing Reporting Persons rolling over their equity.
• Dr. He has stated he will no longer consider a PIPE financing transaction as an alternative to the acquisition proposal.

Sentiment

Score: 7

Explanation: The proposal offers a substantial premium to public shareholders, providing a clear exit strategy at an attractive valuation. However, it also signifies the end of public trading for the company, which could be seen as a loss of investment opportunity for some.

Positives

• The proposed acquisition price of US$1.15 per share offers a 30% premium to the average closing price over the last 30 trading days for public shareholders.
• Provides an immediate cash exit opportunity for public shareholders.

Negatives

• The company would be delisted from Nasdaq, removing public trading access and future investment opportunities in the public market.
• Dr. He will no longer consider a PIPE financing alternative, removing a potential source of future funding for the company if the acquisition does not proceed.

Risks

• The proposal is preliminary and non-binding, subject to negotiation, due diligence, and the execution of definitive agreements.
• The acquisition requires approval by the Company's shareholders.
• Financing for the acquisition (debt and equity) needs to be secured and is subject to terms and conditions.
• The transaction may not be completed, leaving shareholders in the current public company structure.

Future Outlook

If the proposed acquisition is completed, CASI Pharmaceuticals, Inc. would become a privately held company, leading to the delisting of its ordinary shares from the Nasdaq Stock Market and termination of its SEC registration. The company's future strategic direction would be determined by the new private ownership, potentially allowing for more focused long-term strategies away from public market pressures.

Management Comments

• "I believe that my Proposal provides a very attractive opportunity for the Company's shareholders to realize substantial and immediate returns." (Dr. Wei-Wu He)
• "I am interested only in acquiring the outstanding Ordinary Shares of the Company that are not already owned by me or my affiliates, and that I do not intend to sell my Ordinary Shares in the Company to any third party." (Dr. Wei-Wu He)
• "Due to the change of the circumstances, I will not consider any PIPE financing transaction as an alternative." (Dr. Wei-Wu He)

Industry Context

This "going private" transaction reflects a trend where insiders or large shareholders seek to acquire full control of a company, often to pursue long-term strategies away from public market pressures or when they believe the public market undervalues the company. For a biotechnology or pharmaceutical company like CASI, this could allow for more focused R&D investment or strategic shifts without quarterly scrutiny.

Comparison to Industry Standards

• The 30% premium offered is a reasonable premium for a going-private transaction, often falling within typical ranges for such deals, which can vary widely based on market conditions, company specifics, and negotiation dynamics.
• Comparable transactions in the biotech/pharma sector for smaller, publicly traded companies going private often see premiums in the 20-40% range, depending on the company's financial health, pipeline, and market sentiment. Specific comparable companies or projects are not mentioned in the filing to provide a direct comparison.

Related Party Transactions

• Dr. Wei-Wu He, a director of CASI Pharmaceuticals, Inc., is the proposer of the acquisition.
• Reporting Persons, including Dr. He and entities affiliated with him, intend to roll over their equity interests into the Acquisition Vehicle.

Stakeholder Impact

• Shareholders: Public shareholders would receive a cash premium for their shares, providing an immediate return. Shareholders who do not wish to sell would no longer have a publicly traded security.
• Employees: No direct impact on employees is mentioned, but a private company structure could lead to changes in compensation, benefits, or strategic direction.
• Customers/Suppliers: No direct impact on customers or suppliers is mentioned, but a change in ownership could influence future business relationships or product strategies.

Next Steps

• The Company's Board of Directors will evaluate the proposal.
• Parties providing financing will require customary due diligence on the Company.
• Negotiation and finalization of mutually satisfactory definitive agreements.
• Shareholder approval of the terms of the proposal.

Key Dates

Recommendation

For existing shareholders, holding the stock appears prudent given the proposed US$1.15 per share cash offer, which represents a significant 30% premium over recent trading averages. This provides a clear, attractive exit opportunity. However, the non-binding nature and required approvals introduce some risk, so monitoring deal progression is essential. For new investors, this could present an arbitrage opportunity if the market price is below the offer price, assuming a high probability of deal completion.

Keywords

CASI Pharmaceuticals, Going Private, Acquisition, Tender Offer, Delisting, Shareholder Proposal, Wei-Wu He, Biotechnology, Pharmaceuticals, SEC Filing, Schedule 13D